Using the term “polymyalgia rheumatica”, we searched Medline, Embase, Web of Science, and Scopus. We largely selected publications from the past 5 years, but did not exclude widely referenced and highly regarded older publications. The reference lists of articles identified by the search strategy were also reviewed, and articles judged relevant were included. Case reports, scientific abstracts, and articles that included only patients with giant cell arteritis were excluded. Review articles are
SeminarPolymyalgia rheumatica
Introduction
Polymyalgia rheumatica is a chronic, inflammatory disorder of unknown cause. It is not typically seen in people under age 50 years. Clinically, the disorder is characterised by pain and long-term morning stiffness affecting the neck, shoulders, hips, upper arms, and thighs. There are no specific diagnostic tests; diagnosis is typically based on clinical presentation and evidence of systemic inflammation. Ultrasonography of the shoulders and hips is a useful imaging modality in the initial assessment and often shows findings of bursitis, tenosynovitis, or synovitis. The differential diagnosis is broad and clinicians need to consider several disorders that can mimic the disease. In particular, late-onset spondyloarthritis and rheumatoid arthritis can present with polymyalgic symptoms. A well known association exists between polymyalgia rheumatica and giant cell arteritis, a systemic, granulomatous vasculitis that affects the aorta and its branches.
Section snippets
Epidemiology
711 000 people aged 50 years or older in the USA have polymyalgia rheumatica, according to one estimate.1 From population-based incidence studies in Olmsted County, MN, USA, the lifetime risk of developing the disease has been estimated at 2·43% for women and 1·66% for men.2 Polymyalgia rheumatica occurs almost exclusively in people older than age 50 years, and the mean age of onset is about 73 years. In general, its incidence increases with advancing age,3 and varies by geographical region.
Aetiology and pathogenesis
The cause of polymyalgia rheumatica is unknown. Epidemiological studies suggest that both genetic and environmental factors might be important in disease pathogenesis. Although familial aggregation is rare, it has been described.13 Several studies have reported an association between the disorder and specific polymorphisms in genes related to immune regulation.11 Genetic polymorphisms associated with disease risk or severity include intercellular adhesion molecule 1, interleukin 1 receptor
Polymyalgia rheumatica and giant cell arteritis
Polymyalgia rheumatica and giant cell arteritis share many similarities, including age at onset, female predominance, and similar geographical distribution, suggesting that they might represent different types of the same disease. Clinically, 40–60% of patients with giant cell arteritis have polymyalgia rheumatica symptoms at diagnosis.35 Additionally, 16–21% of patients with polymyalgia rheumatica have giant cell arteritis.35 Both diseases are characterised by a chronic inflammatory state,
Clinical features
Patients present with characteristic pain and stiffness affecting the shoulder girdle, hip girdle, and neck muscles. The pain can radiate to the elbows or knees. Patients often report morning stiffness lasting 30 min or longer and worsening stiffness after periods of rest. Symptoms are usually bilateral. Constitutional symptoms, including fatigue, malaise, anorexia, weight loss, and fever (usually low-grade), can occur in 40–50% of patients.40 In view of the association between polymyalgia
Diagnosis
Polymyalgia rheumatica is a clinical diagnosis. At initial presentation, to think of it as a polymyalgia syndrome is helpful, and a careful history and physical examination are crucial in distinguishing it from other disorders that mimic it (panel 1).52 Several sets of diagnostic criteria have been proposed (panel 2).40, 53, 54, 55 An age cutoff is used in most of these systems. Other common criteria are the presence of bilateral shoulder girdle and hip girdle aching, morning stiffness, and a
Treatment and follow-up
The standard treatment is low-dose glucocorticoids, which characteristically induce rapid resolution of symptoms. There have been no controlled clinical trials assessing the efficacy of glucocorticoids compared with placebo. A systematic review of studies of treatment has been reported.77 Although the high degree of variation between studies precluded the researchers from calculating pooled estimates, they were able to make several treatment recommendations.77 A set of guidelines for management
Prognosis
Response to treatment is assessed on the basis of symptoms and markers of inflammation. Despite therapy, relapses are common and arise in roughly 50% of patients.94, 95 Factors that have been associated with relapses or long-term glucocorticoid therapy are a higher initial dose of glucocorticoids,94 rapid glucocorticoid taper,94 and female sex.31, 80 Persistently raised CRP and interleukin 6 might also be associated with risk of relapses.95 Several studies have shown increased circulating
Future perspectives
Disease-specific biomarkers for polymyalgia rheumatica are currently unavailable. Additionally, heterogeneity exists between patients and some have an underlying inflammatory vasculopathy. Therefore, diagnostic biomarkers that allow prompt and accurate diagnosis are eagerly awaited. Discovery and validation of such markers will require collaborative, prospective studies in which patients are assessed and treated in a standardised way, such as that recently undertaken by the EULAR-ACR
Search strategy and selection criteria
References (103)
- et al.
Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica
Semin Arthritis Rheum
(2003) - et al.
Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory chronic conditions: Association of IL-1RN*2/2 genotype with polymyalgia rheumatica
Hum Immunol
(2009) - et al.
Polymyalgia rheumatica and giant-cell arteritis
Lancet
(2008) Long-term follow-up of polymyalgia rheumatica: evidence for synovitis
Semin Arthritis Rheum
(1984)- et al.
Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study
Semin Arthritis Rheum
(2000) - et al.
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II
Arthritis Rheum
(2008) - et al.
The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases
Arthritis Rheum
(2011) - et al.
Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA
J Rheumatol
(2002) - et al.
Epidemiology of giant cell arteritis and polymyalgia rheumatica
Arthritis Rheum
(2009) - et al.
The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987–94
J Rheumatol
(1997)
Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001
Ann Rheum Dis
Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection
J Rheumatol
Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A prospective investigation, 1982–1985
Arthritis Rheum
Epidemiology and mortality in 220 patients with polymyalgia rheumatica
Br J Rheumatol
Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy
Arthritis Rheum
The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study
J Rheumatol
Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: Clinical features and epidemiological data
Clin Exp Rheumatol
Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families
Clin Exp Rheumatol
Relationship between interleukin 6 promoter polymorphism at position −174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica
J Rheumatol
Polymyalgia rheumatica prevalence in a population-based sample
Arthritis Rheum
A seasonal pattern in the onset of polymyalgia rheumatica
Ann Rheum Dis
Seasonal pattern in the onset of polymyalgia rheumatica
Ann Rheum Dis
Proximal bursitis in active polymyalgia rheumatica
Ann Intern Med
Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients
J Rheumatol
Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study
J Rheumatol
Cervical interspinous bursitis in active polymyalgia rheumatica
Ann Rheum Dis
Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients
Rheumatology (Oxford)
Ultrasonographic evidence of synovitis in axial joints in patients with polymyalgia rheumatica
Br J Rheumatol
Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment
Arthritis Rheum
Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica
Arthritis Rheum
The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica
Rheumatology (Oxford)
Further evidence for insufficient hypothalamic-pituitary-glandular axes in polymyalgia rheumatica
J Rheumatol
Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure
Neuroendocrinology
Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis
Ann Rheum Dis
Low serum levels of DHEAS in untreated polymyalgia rheumatica/giant cell arteritis
J Rheumatol
Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6
J Rheumatol
Evaluation of the hypothalamic-pituitary-adrenal axis in untreated patients with polymyalgia rheumatica and healthy controls
Scand J Rheumatol
Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity
Arthritis Rheum
Circulating cytokines in active polymyalgia rheumatica
Ann Rheum Dis
Giant-cell arteritis and polymyalgia rheumatica
Ann Intern Med
Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis
Ann Intern Med
Polymyalgia rheumatica: a 10-year epidemiologic and clinical study
Ann Intern Med
Polymyalgia rheumatica: a disorder of extraarticular synovial structures?
J Rheumatol
The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain
J Rheumatol
Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study
Ann Rheum Dis
A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis
Br J Rheumatol
The incidence and clinical characteristics of peripheral arthritis in polymyalgia rheumatica and temporal arteritis: a prospective study of 231 cases
Rheumatology (Oxford)
Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study
Arthritis Rheum
Distal musculoskeletal manifestations in polymyalgia rheumatica
Clin Exp Rheumatol
Peripheral musculoskeletal manifestations in polymyalgia rheumatica
J Clin Rheumatol
Cited by (109)
Whole-Body Magnetic Resonance Imaging in Rheumatology
2024, Radiologic Clinics of North AmericaGiant Cell Arteritis and Polymyalgia Rheumatica: Treatment Approaches and New Targets
2023, Rheumatic Disease Clinics of North AmericaConcurrent baseline diagnosis of giant cell arteritis and polymyalgia rheumatica – A systematic review and meta-analysis
2022, Seminars in Arthritis and RheumatismTreatment and Outcomes of Acute Myocardial Infarction in Patients With Polymyalgia Rheumatica With and Without Giant Cell Arteritis
2022, American Journal of CardiologyPET imaging in vasculitis
2022, Nuclear Medicine and Molecular Imaging: Volume 1-4Autoimmune disease of the cardiovascular system
2022, Translational Autoimmunity: Autoimmune Disease Associated with Different Clinical Features